{"id":"topiramate","brandName":"Topamax","genericName":"topiramate","companyId":"johnson-johnson","companyName":"Janssen","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"10155 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"7256 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"6820 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"5912 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"5499 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"4532 reports"},{"date":"","signal":"MIGRAINE","source":"FDA FAERS","actionTaken":"4429 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"4384 reports"},{"date":"","signal":"SEIZURE","source":"FDA FAERS","actionTaken":"3776 reports"},{"date":"","signal":"DEPRESSION","source":"FDA FAERS","actionTaken":"3694 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Paresthesia","drugRate":"40%","severity":"common","organSystem":""},{"effect":"Weight loss","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Abnormal vision","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Difficulty with memory","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Psychomotor slowing","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Speech disorders/related speech problems","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Nervousness","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Taste perversion","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Hypoesthesia","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Upper respiratory tract infection","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Confusion","drugRate":"3%","severity":"common","organSystem":""}],"contraindications":["Concentration Difficulty","Depressive disorder","Diarrhea","Diminished sweating","Disease of liver","Dizziness","Drowsy","Fatigue","Fever","Impaired cognition","Kidney disease","Kidney stone","Memory impairment","Metabolic acidosis","Mood swings","Ocular hypertension","Paresthesia","Pregnancy, function","Reduced visual acuity","Secondary angle-closure glaucoma","Suicidal thoughts"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Difficulty with concentration/attention","drugRate":"2%","severity":"serious"},{"effect":"Flushing","drugRate":"2%","severity":"serious"},{"effect":"Asthenia","drugRate":"2%","severity":"serious"}]},"trials":["NCT01859013","NCT00236873","NCT02659475","NCT01682681","NCT02283814","NCT06299891","NCT00404248","NCT00796367","NCT00704860","NCT00206336","NCT00812006","NCT00231634","NCT00236509","NCT00208130","NCT02098941","NCT00006205","NCT06877572","NCT00210860","NCT05925959","NCT03280342","NCT00286988","NCT00648934","NCT02884050","NCT03712917","NCT03120468","NCT01922934","NCT00236665","NCT00210574","NCT04581603","NCT00768677","NCT00755716","NCT00236860","NCT03511118","NCT01970566","NCT05516251","NCT00905567","NCT00518466","NCT00231647","NCT04095104","NCT00486291","NCT05263674","NCT02300051","NCT06089356","NCT05958160","NCT00732108","NCT00001725","NCT05759845","NCT01030094","NCT06972056","NCT01581281"],"indications":{"approved":[{"name":"Epilepsy characterized by intractable complex partial seizures","diseaseId":"epilepsy-characterized-by-intractable-complex-partial-seizures","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lennox-Gastaut syndrome","diseaseId":"lennox-gastaut-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Migraine Prevention","diseaseId":"migraine-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Simple partial seizure","diseaseId":"simple-partial-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tonic-clonic epilepsy","diseaseId":"tonic-clonic-epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[{"type":"Formulation","number":"9622983","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Formulation","number":"8298576","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2028-04-04"},{"type":"Formulation","number":"8663683","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Formulation","number":"8992989","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Method of Use","number":"8889191","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Formulation","number":"9549940","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Formulation","number":"8298580","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Formulation","number":"8877248","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Formulation","number":"9555004","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Method of Use","number":"10363224","applicant":"UPSHER SMITH LABORATORIES LLC","territory":"US","tradeName":"QUDEXY XR","expiryDate":"2033-03-19"},{"type":"Formulation","number":"10314790","applicant":"SUPERNUS PHARMACEUTICALS INC","territory":"US","tradeName":"TROKENDI XR","expiryDate":"2027-11-16"},{"type":"Method of Use","number":"11433046","applicant":"AZURITY PHARMACEUTICALS INC","territory":"US","tradeName":"EPRONTIA","expiryDate":"2040-08-21"},{"type":"Formulation","number":"12290503","applicant":"AZURITY PHARMACEUTICALS INC","territory":"US","tradeName":"EPRONTIA","expiryDate":"2040-08-21"},{"type":"Formulation","number":"11911362","applicant":"AZURITY PHARMACEUTICALS INC","territory":"US","tradeName":"EPRONTIA","expiryDate":"2040-08-21"},{"type":"Formulation","number":"9555005","applicant":"UPSHER SMITH LABORATORIES LLC","territory":"US","tradeName":"QUDEXY XR","expiryDate":"2033-03-19"},{"type":"Formulation","number":"11826343","applicant":"AZURITY PHARMACEUTICALS INC","territory":"US","tradeName":"EPRONTIA","expiryDate":"2040-08-21"},{"type":"Formulation","number":"9101545","applicant":"UPSHER SMITH LABORATORIES LLC","territory":"US","tradeName":"QUDEXY XR","expiryDate":"2033-03-19"},{"type":"Formulation","number":"8889190","applicant":"UPSHER SMITH LABORATORIES LLC","territory":"US","tradeName":"QUDEXY XR","expiryDate":"2033-03-19"},{"type":"Formulation","number":"8652527","applicant":"UPSHER SMITH LABORATORIES LLC","territory":"US","tradeName":"QUDEXY XR","expiryDate":"2033-03-19"},{"type":"Formulation","number":"11633374","applicant":"AZURITY PHARMACEUTICALS INC","territory":"US","tradeName":"EPRONTIA","expiryDate":"2040-08-21"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT01859013","phase":"Phase 2","title":"BMI Reduction With Meal Replacements + Topiramate in Adolescents With Severe Obesity","status":"COMPLETED","sponsor":"University of Minnesota","isPivotal":false,"enrollment":34,"indication":"Obesity, Morbid, Obesity","completionDate":"2017-04"},{"nctId":"NCT00236873","phase":"Phase 2","title":"Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":false,"enrollment":47,"indication":"Epilepsy, Epilepsies, Partial","completionDate":"1993-05"},{"nctId":"NCT02659475","phase":"Phase 2","title":"Open-label Phentermine/Topiramate Extended Release (PHEN/TPM ER; Qsymia®) in Ten Subjects With Overweight or Obesity and DSM-V Binge Eating Disorder (BED)","status":"COMPLETED","sponsor":"Lindner Center of HOPE","isPivotal":false,"enrollment":10,"indication":"Binge Eating Disorder","completionDate":"2016-09"},{"nctId":"NCT01682681","phase":"N/A","title":"A Prospective, Observational, Multi-center Study to Assess Long-term Retention Rate of Topiramate in Patients With Epilepsy","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","isPivotal":false,"enrollment":1234,"indication":"Epilepsy","completionDate":"2009-05"},{"nctId":"NCT02283814","phase":"Phase 1","title":"A Phase-1, Open-label, Drug Interaction Study Between Eslicarbazepine Acetate 1200 mg and Topiramate 200 mg Following Multiple Dose Administrations in Healthy Male","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","isPivotal":false,"enrollment":32,"indication":"Epilepsy","completionDate":"2007-02"},{"nctId":"NCT06299891","phase":"Phase 2","title":"Phentermine/Topiramate in Children, Adolescents, and Young Adults With Hypothalamic Obesity: a Pilot and Feasibility Study","status":"RECRUITING","sponsor":"Seattle Children's Hospital","isPivotal":false,"enrollment":24,"indication":"Hypothalamic Obesity, Hypothalamic Tumor","completionDate":"2026-05-31"},{"nctId":"NCT00404248","phase":"Phase 1","title":"Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":35,"indication":"Brain and Central Nervous System Tumors","completionDate":"2012-02"},{"nctId":"NCT00796367","phase":"Phase 3","title":"A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adu","status":"COMPLETED","sponsor":"VIVUS LLC","isPivotal":true,"enrollment":676,"indication":"Obesity","completionDate":"2010-07"},{"nctId":"NCT00704860","phase":"Phase 4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","isPivotal":false,"enrollment":27,"indication":"Major Depression","completionDate":"2010-12"},{"nctId":"NCT00206336","phase":"Phase 3","title":"An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286)","status":"COMPLETED","sponsor":"Baylor College of Medicine","isPivotal":true,"enrollment":20,"indication":"Tourette Syndrome","completionDate":"2008-12"},{"nctId":"NCT00812006","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topira","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":108,"indication":"Migraine","completionDate":"2009-10-22"},{"nctId":"NCT00231634","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Inadequately Controlled o","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":true,"enrollment":31,"indication":"Obesity, Diabetes Mellitus, Type 2","completionDate":"2002-11"},{"nctId":"NCT00236509","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":true,"enrollment":763,"indication":"Migraine, Common Migraine","completionDate":"2002-09"},{"nctId":"NCT00208130","phase":"Phase 4","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians","status":"COMPLETED","sponsor":"Creighton University","isPivotal":false,"enrollment":60,"indication":"Post-Traumatic Stress Disorder","completionDate":"2004-03"},{"nctId":"NCT02098941","phase":"N/A","title":"A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment","status":"UNKNOWN","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":2500,"indication":"Epilepsy","completionDate":"2014-12"},{"nctId":"NCT00006205","phase":"Phase 2","title":"Combining Medications Treatment for Alcoholism","status":"UNKNOWN","sponsor":"Bankole Johnson","isPivotal":false,"enrollment":320,"indication":"Alcoholism","completionDate":"2013-12"},{"nctId":"NCT06877572","phase":"N/A","title":"Enacting Active Survivorship: Implementation of Weight Management Strategies in Endometrial Cancer Survivors","status":"RECRUITING","sponsor":"University of Kansas Medical Center","isPivotal":false,"enrollment":50,"indication":"Endometrial Cancer Survivors, Weight Management","completionDate":"2030-10"},{"nctId":"NCT00210860","phase":"Phase 3","title":"An Open-label Study of the Safety and Efficacy of Topiramate for Migraine Prophylaxis: Extension Study to CAPSS-277","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":true,"enrollment":142,"indication":"Migraine","completionDate":"2006-03"},{"nctId":"NCT05925959","phase":"NA","title":"Preoperative Weight Loss for Open Abdominal Wall Reconstruction","status":"RECRUITING","sponsor":"Benjamin T. Miller","isPivotal":false,"enrollment":258,"indication":"Abdominal Wall Hernia","completionDate":"2027-06-01"},{"nctId":"NCT03280342","phase":"Phase 2","title":"Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine","status":"WITHDRAWN","sponsor":"University of Minnesota","isPivotal":false,"enrollment":0,"indication":"Migraine, Headache","completionDate":"2018-09-13"},{"nctId":"NCT00286988","phase":"Phase 4","title":"Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children","status":"TERMINATED","sponsor":"Monarch Medical Research","isPivotal":false,"enrollment":12,"indication":"Vomiting","completionDate":"2007-06"},{"nctId":"NCT00648934","phase":"Phase 1","title":"Single-Dose Fed Bioequivalence Study of Topiramate Sprinkle Capsules (25 mg; Mylan) and Topamax® Sprinkle Capsules (25 mg; Ortho-McNeil Neurologics) in Healthy Volunteers","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":36,"indication":"Healthy","completionDate":"2005-12"},{"nctId":"NCT02884050","phase":"Phase 1","title":"Physiologic Effects of Topiramate on Cognition","status":"COMPLETED","sponsor":"University of Florida","isPivotal":false,"enrollment":11,"indication":"Alteration of Cognitive Function","completionDate":"2011-01"},{"nctId":"NCT03712917","phase":"NA","title":"Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine: A Randomised Parallel Group Study","status":"COMPLETED","sponsor":"Ataturk University","isPivotal":false,"enrollment":120,"indication":"Migraine","completionDate":"2019-03-31"},{"nctId":"NCT03120468","phase":"EARLY/Phase 1","title":"Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder","status":"UNKNOWN","sponsor":"Nassima Ait-Daoud Tiouririne","isPivotal":false,"enrollment":16,"indication":"Alcoholism","completionDate":"2021-01"},{"nctId":"NCT01922934","phase":"Phase 4","title":"A Toolbox Approach to Obesity Treatment in Primary Care","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","isPivotal":false,"enrollment":4730,"indication":"Obesity","completionDate":"2016-08"},{"nctId":"NCT00236665","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertensi","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":true,"enrollment":531,"indication":"Obesity, Hypertension","completionDate":"2002-06"},{"nctId":"NCT00210574","phase":"Phase 2","title":"A Pilot Study of Topiramate in Childhood Absence Epilepsy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":false,"enrollment":12,"indication":"Epilepsy, Absence","completionDate":"2006-10"},{"nctId":"NCT04581603","phase":"Phase 4","title":"Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in Promoting Abstinence in Alcohol Use Disorder (AUD)","status":"TERMINATED","sponsor":"VA Office of Research and Development","isPivotal":false,"enrollment":82,"indication":"Alcohol Use Disorder With Insomnia","completionDate":"2025-01-20"},{"nctId":"NCT00768677","phase":"NA","title":"Open-Label Study of Topiramate for Binge Eating Disorder and Bulimia Nervosa Among Adolescents","status":"COMPLETED","sponsor":"The Zucker Hillside Hospital","isPivotal":false,"enrollment":0,"indication":"Eating Disorders, Bulimia Nervosa","completionDate":""},{"nctId":"NCT00755716","phase":"Phase 3","title":"Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study","status":"COMPLETED","sponsor":"UConn Health","isPivotal":true,"enrollment":57,"indication":"Tobacco Dependence","completionDate":"2013-08"},{"nctId":"NCT00236860","phase":"Phase 2","title":"Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":false,"enrollment":56,"indication":"Epilepsy, Epilepsies, Partial","completionDate":"1992-02"},{"nctId":"NCT03511118","phase":"N/A","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","isPivotal":false,"enrollment":1600,"indication":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","completionDate":"2027-07-31"},{"nctId":"NCT01970566","phase":"NA","title":"Effect of Intense-Exercise/Moderate-Calorie vs Topiramate-Phentermine on Obesity","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","isPivotal":false,"enrollment":0,"indication":"Obesity, Diabetes Mellitus","completionDate":"2017-11"},{"nctId":"NCT05516251","phase":"NA","title":"Transcutaneous Supraorbital Nerve Stimulator Versus Topiramate in Prevention of Recurrent Migraine: A Prospective, Randomized Comparative Study.","status":"UNKNOWN","sponsor":"Tongji Hospital","isPivotal":false,"enrollment":200,"indication":"Migraine, Classic","completionDate":"2023-09-30"},{"nctId":"NCT00905567","phase":"Phase 1","title":"Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Tablets Administered as 2 x 25 mg Tablets in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","isPivotal":false,"enrollment":24,"indication":"Healthy","completionDate":"2001-06"},{"nctId":"NCT00518466","phase":"Phase 1","title":"A Phase Ib, Open Label, Parallel-Design Single- and Multiple-Dose Study Comparing Modified Release Topiramate Formulations to Immediate Release Formulations of Topiramate Dosed in Combination With Imm","status":"COMPLETED","sponsor":"VIVUS LLC","isPivotal":false,"enrollment":64,"indication":"Obesity","completionDate":"2007-12"},{"nctId":"NCT00231647","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of Topiramate OROS Controlled-Release in the Treatment of Obese, Type 2 Diabetic Sub","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":false,"enrollment":113,"indication":"Obesity, Diabetes Mellitus, Type 2","completionDate":"2004-10"},{"nctId":"NCT04095104","phase":"Phase 2","title":"Adjunctive Anti-Obesity Pharmacotherapy in Adolescents and Young Adults After Bariatric Surgery: A Randomized Controlled Pilot Study","status":"COMPLETED","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":13,"indication":"Obesity, Morbid, Bariatric Surgery","completionDate":"2022-01-25"},{"nctId":"NCT00486291","phase":"Phase 2","title":"A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults","status":"COMPLETED","sponsor":"VIVUS LLC","isPivotal":false,"enrollment":210,"indication":"Type 2 Diabetes Mellitus","completionDate":"2008-04"},{"nctId":"NCT05263674","phase":"Phase 3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","isPivotal":true,"enrollment":140,"indication":"Non-Convulsive Status Epilepticus","completionDate":"2028-12-31"},{"nctId":"NCT02300051","phase":"NA","title":"Sexual Risk Behavior, Clinical and Psychopathological Aspects of Individuals With Compulsive Sexual Behavior of the Institute of Psychiatry of the General Hospital of the University of São Paulo Medic","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","isPivotal":false,"enrollment":135,"indication":"Compulsive Sexual Behavior","completionDate":"2015-07"},{"nctId":"NCT06089356","phase":"Phase 4","title":"Zolmitriptane as Prophylactic Therapy Childhood Migraine","status":"UNKNOWN","sponsor":"Tanta University","isPivotal":false,"enrollment":90,"indication":"Migraine","completionDate":"2024-01-01"},{"nctId":"NCT05958160","phase":"Phase 2","title":"Modified Atkins Diet Versus Topiramate In Children With Epileptic Spasms Refractory To Hormonal Treatment: A Randomized Open-Label Study","status":"UNKNOWN","sponsor":"Lady Hardinge Medical College","isPivotal":true,"enrollment":70,"indication":"Epileptic Spasms, Failed Hormonal Therapy","completionDate":"2024-10-31"},{"nctId":"NCT00732108","phase":"NA","title":"Efficacy of Topiramate in Patients Wih Migraine-Associated Dizziness","status":"WITHDRAWN","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":0,"indication":"Migraine, Headache","completionDate":""},{"nctId":"NCT00001725","phase":"Phase 2","title":"Clinical Trials in Orofacial Neuralgias","status":"COMPLETED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","isPivotal":false,"enrollment":100,"indication":"Facial Neuralgia, Pain","completionDate":"2002-01"},{"nctId":"NCT05759845","phase":"Phase 4","title":"Topiramate, Amitriptyline Monotherapy and Combination Therapy in Migraine Prophylaxis: An Open Label Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Dr. Reaz Mahmud","isPivotal":false,"enrollment":150,"indication":"Migraine","completionDate":"2023-05-31"},{"nctId":"NCT01030094","phase":"N/A","title":"A Cross-sectional, Comparative, Multi-center Study to Investigate the Effect of Topiramate Monotherapy on Markers of Bone Mineral Metabolism and Bone Mineral Density in Premenopausal Women With Epilep","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","isPivotal":false,"enrollment":140,"indication":"Seizures, Convulsions","completionDate":"2009-04"},{"nctId":"NCT06972056","phase":"Phase 4","title":"A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study","status":"RECRUITING","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":1335,"indication":"Migraine","completionDate":"2029-12-01"},{"nctId":"NCT01581281","phase":"Phase 3","title":"Amitriptyline and Topiramate in the Prevention of Childhood Migraine","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","isPivotal":true,"enrollment":488,"indication":"Migraine, Migraine Disorders","completionDate":"2016-01"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0656/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$24","description":"TOPIRAMATE 100 MG TABLET","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-10-30T00:00:00.000Z","mah":"SUN PHARM","brand_name_local":null,"application_number":"ANDA090278"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-03-08T00:00:00.000Z","mah":"CIPLA LTD","brand_name_local":null,"application_number":"ANDA076343"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-07-17T00:00:00.000Z","mah":"ASCENT PHARMS INC","brand_name_local":null,"application_number":"ANDA215414"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-05-27T00:00:00.000Z","mah":"RUBICON RESEARCH","brand_name_local":null,"application_number":"ANDA216683"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-03-18T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":null,"application_number":"ANDA218482"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"9622983","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8663683","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8992989","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8889191","territory":"US","patent_type":"Method of Use","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9549940","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8298580","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8877248","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9555004","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10314790","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8298576","territory":"US","patent_type":"Formulation","expiry_date":"2028-04-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10363224","territory":"US","patent_type":"Method of Use","expiry_date":"2033-03-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9555005","territory":"US","patent_type":"Formulation","expiry_date":"2033-03-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9101545","territory":"US","patent_type":"Formulation","expiry_date":"2033-03-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8889190","territory":"US","patent_type":"Formulation","expiry_date":"2033-03-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8652527","territory":"US","patent_type":"Formulation","expiry_date":"2033-03-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11826343","territory":"US","patent_type":"Formulation","expiry_date":"2040-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11433046","territory":"US","patent_type":"Method of Use","expiry_date":"2040-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11633374","territory":"US","patent_type":"Formulation","expiry_date":"2040-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12290503","territory":"US","patent_type":"Formulation","expiry_date":"2040-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11911362","territory":"US","patent_type":"Formulation","expiry_date":"2040-08-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":7,"withResults":3},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=topiramate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:29:51.130105+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:29:51.130001+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:29:58.571791+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:29:49.752691+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=topiramate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:29:59.423721+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:48.025072+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:48.025129+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:30:00.932924+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: GABA-A receptor; anion channel positive modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:29:59.975255+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL220492/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:29:59.881209+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA090278","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:48.025139+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:30:05.918023+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL220492"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}